Chris Burns

Poster presentation at AACR Ras conference, entitled Combination benefit of FAK inhibitor narmafotinib and KRAS inhibitors

I'll be attending next month's AACR Special Conference on Ras Oncogenesis and Therapeutics in Los Angeles to present a poster describing Amplia's preclinical studies of various kRAS inhibitors with our best-in-class FAK inhibitor narmafotinib.
#AACRras26 #FAK #pancreaticcancer

Amplia Therapeutics (ASX:ATX; OTCQB:INNMF) has announced the successful completion its first large-scale manufacturing campaign of narmafotinib, producing approximately 13 kg of active pharmaceutical ingredient (API). Read the ASX release: bit.ly/4bayyuN
#pancreaticcancer #FAK

Amplia has reported a further confirmed PR in the ACCENT trial evaluating FAK inhibitor narmafotinib in combination with chemotherapy in metastatic pancreatic cancer. View presentation: ampliatx.com/announcement...

$ATX $INNMF #Amplia #pancreaticcancer #clinicaltrial #FAK

Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX) Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX)

Amplia CEO Dr Chris Burns will present at the Life Sciences Virtual Investor Forum this week, sharing recent achievements and next steps in the development of narmafotinib: 3pm Thur 11 December (US ET) / 7am Fri 12 December (AEDT)
🔗 To register: bit.ly/4ptfJHt
#Amplia #pancreaticcancer #FAK

Triple negative breast cancer remains tough to treat. A new study finds FAK interacts with PD-L1, boosting immune evasion when inhibited. Combining FAK inhibitors with PD-L1 blockade could unlock better therapies.
www.mdpi.com/3547364
#FAK #TNBC #Immunotherapy

Breakthrough Victoria commits $75m to VC funds The Victorian government has made a $75 million investment through Breakthrough Victoria into five venture capital funds, aimed at boosting private capital, supporting early-stage companies and accele...

Breakthrough Victoria commits $75m to VC funds www.innovationaus.com/breakthrough...

Adelaide scientists have identified the cell surface receptor F2R as a promising biomarker and treatment target for ovarian cancer. This breakthrough could improve diagnosis and therapy for women with this deadly disease, especially those with drug-resistant cancers. www.mdpi.com/3481014

Targeting circulating mechanoresponsive monocytes and macrophages to reduce fibrosis Nature Biomedical Engineering - Myeloid-specific mechanotransduction ablation downregulates pro-fibrotic fibroblast transcriptional profiles to reduce scar formation in human cells

New research finds that targeting mechanoresponsive myeloid cells through FAK inhibition reduces fibrosis and scarring by restoring anti-inflammatory cell populations—offering fresh hope for systemic therapies against organ fibrosis. #FAK #Fibrosis #Immunology rdcu.be/eMOrH

ASX:ATX - Amplia Therapeutics to Significantly Expand U.S. Presence Read and interact with this announcement: Amplia Therapeutics to Significantly Expand U.S. Presence on Amplia's investor hub

#Amplia is expanding its U.S. presence to boost investor awareness & engagement. As its Phase 1b/2a AMPLICITY trial continues in the U.S. and Australia, Amplia has launched a U.S. capital markets campaign and is pursuing an OTCQB uplisting. bit.ly/3IRUrmV $ATX #clinicaltrials #pancreaticcancer

New Data | Amplia’s ongoing ACCENT clinical trial in advanced pancreatic cancer has recorded an additional confirmed partial response and one unconfirmed partial response. Read the ASX release: bit.ly/3IQavFG
$ATX $INNMF #Amplia #clinicaltrial #pancreaticcancer #innovation #pharma

As the U.S. dials back mRNA research, the U.K. tries to seize an opportunity As the U.S. dials back mRNA research, the U.K. is trying to seize an opportunity.

As the U.S. dials back mRNA research, the U.K. tries to seize an opportunity www.statnews.com/2025/09/25/m... via @statnews.com

The diagnosis that saved me — and may have misled my mother to her death If I had not survived a rare misdiagnosis, would my mother have fought harder for her own treatment?

The diagnosis that saved me — and may have misled my mother to her death www.statnews.com/2025/09/10/m... via @statnews.com

Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader The conversion of conventional inhibitors of Bcl-xL, a key anti-apoptotic protein, to PROTAC degraders has shown significant promise, particularly in mitigating the on-target thrombocytopenia…

🔓Read recent #OpenAccess work by Daohong Zhou, Guangrong Zheng & co on the potential of CRBN-recruiting Bcl-xL degraders as promising anticancer agents with improved efficacy and manageable platelet toxicity🔥

pubs.rsc.org/en/content/a...

📍 @ufresearch.bsky.social 🧪

$72m boost for Australian medical research More than $72 million in new medical research grants for projects ranging from chronic disease prevention and health equity to artificial intelligence in hospitals were announced by the federal govern...

$72m boost for Australian medical research www.innovationaus.com/72m-boost-fo...

Professor Grant Dewson (left) and Professor Andrew Wei (right)

Two WEHI-led projects tackling Parkinson’s and acute myeloid leukaemia have each received $3m in NHMRC funding over five years as newly announced Centres of Research Excellence.

🔗 Learn more and meet the project leads: www.wehi.edu.au/news/6m-boos...

Australian-led trial shows nasal spray reduces COVID-19 risk in cancer patients - Peter MacCallum Cancer Centre

Share www.petermac.org/about-us/new...

ASX:ATX - AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL Read and interact with this announcement: AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL on Amplia's investor hub

Amplia has announced opening of two Australian trial sites for the Company’s new pancreatic cancer trial investigating narmafotinib with FOLFIRINOX in metastatic pancreatic cancer patients.
Read the ASX release: bit.ly/ATX-Sites-Open

#pancreaticcancer #clinicaltrial #FOLFORINOX #FAK

Let's not waste our multibillion-dollar biotech opportunity Australia’s life sciences industry is a quiet and unfortunately, regularly misunderstood achiever. With billions in annual revenues, the sector not only delivers world-class research, it also provides...

Let’s not waste our multibillion-dollar biotech opportunity www.innovationaus.com/lets-not-was...

Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors PURPOSEThis early-phase study evaluated safety/tolerability, pharmacokinetics, and preliminary efficacy of dendrimer-nanoparticle delivery platform (DEP)-SN38, a polylysine-based nanoparticle conjugat...

Great to see this work, using Starpharma's drug, published.

Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1...

Are you a top US-based scientist wanting to relocate to Australia? We are now calling for formal applications from both Australian and non-Australian citizens based in the US whose work is internationally recognised as exceptional.
📅 Applications close: Aug 29, 2025
🔗 science.org.au/gtap/?utm_so...

Monash's $15m pre-seed fund backs first spinouts Three Victorian HealthTech startups have secured pre-seed funding from Breakthrough Victoria and Monash University, marking the official launch of a new $15 million fund and the university’s new comme...

This is great news, though can't help to wonder where is BioCurate?
Monash’s $15m pre-seed fund backs first spinouts www.innovationaus.com/monashs-15m-...

Amplia has announced that it has received Australian ethics approval for the Ph2 trial of narmafotinib in combination with FOLFIRINOX in advanced pancreatic cancer.
Read the ASX release: bit.ly/ATX_AU_Ethics

$ATX #Amplia #clinicaltrials #pancreaticcancer #cancertherapeutics

Qld super mandate directs $50m to local startups A new $50 million investment mandate will see Queenslanders’ retirement savings channelled back into the state’s economy, with Brighter Super and Queensland Investment Corporation joining forces to ba...

Excellent news!!!
Qld super mandate directs $50m to local startups www.innovationaus.com/qld-super-ma...

Amplia Therapeutics has announced 17th confirmed partial response (PR) has been recorded in the Company’s ongoing ACCENT clinical trial in pancreatic cancer. Read the ASX release: bit.ly/ATX_17th_PR
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX

RSC Medicinal Chemistry outside front cover for vol 16, issue 6.

This week's front cover features a Review by Taebo Sim and colleagues on the recent developments in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma, read it here👀

pubs.rsc.org/en/content/a...

📍Korea University and Yonsei University 🧪

Amplia Therapeutics Limited Read and interact with this announcement: Second Complete Response in ACCENT Pancreatic Cancer Trial on Amplia's investor hub

#Amplia has announced that a second patient enrolled in the ACCENT trial has recorded a confirmed complete response (CR). Read the ASX release tinyurl.com/33ez5srv

#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX

Registration | Twilight with PTX & ATX Date: Wed, 9 July 2025 Time: 4.15pm arrival for 4.30pm start Venue: Detail to be provided upon RSVP confirmation Inquiry: info@monsoon.com.au

I'll be speaking about narmafotinib and pipeline progress at #TwilightInvestorBriefing in Melbourne July 9th.

🔗 RSVP now: bit.ly/reg-twilight-ptx-atx

#ASX #biotech #oncology #pancreaticcancer

Amplia Therapeutics Limited Read and interact with this announcement: Pathological Complete Response in Pancreatic Cancer Trial on Amplia's investor hub

A patient from Amplia's ACCENT clinical trial in advanced pancreatic cancer has now recorded a pathological complete response (pCR) - an extremely rare observation in this patient population. Read the ASX release: bit.ly/ATX_pCR

$ATX #Amplia #pancreaticcancer #clinicaltrial #pharma #biotech #ASX

Dr Boreham's Crucible: This pancreatic cancer tackler has faith its 'good science will prevail' - Stockhead Amplia Therapeutics is making strides with its candidate that works on the anti-fibrotic path to tackling pancreatic cancer.

Great to speak with Tim Boreham about Amplia Therapeutics' progress and plans. stockhead.com.au/health/dr-bo...

New research shows combining FAK & MEK inhibitors is a promising strategy to tackle aggressive glioblastoma (GBM). This combination therapy significantly reduced tumor growth in models of disease
www.mdpi.com/1999-4923/17...
#glioblastoma #braintumor #targetedtherapy #FAK #MEK

@uoe-igc.bsky.social